"Innovation is found where people, ideas
and technologies intersect."

Patrick Verheyen, Head J&J London Innovation Center

"We need to join forces if we want to solve
Alzheimer's Disease."

Bart De Strooper, Professor at VIB and KU Leuven, Co-director LIND

A framework for collaboration in neurodegenerative diseases

At Janssen Research & Development, we are deeply committed to patients with neurodegenerative diseases and to the health care professionals who care for them. Our goal is to develop a culture of innovation and bring forth new treatments for those with great unmet medical need.

Our strategy is to harness the best science in the world, both from our own laboratories and through strategic relationships and collaborations with academia and knowledge centers. Collaboration will drive the types of discoveries that will ultimately improve the prevention, diagnosis and treatment of neurodegenerative diseases for generations.

We are dedicated to partnering with others who share our vision and want to work together to build the treatments of tomorrow for neurodegenerative diseases. We believe that partners are essential to driving change, innovation and transformation, and we are committed to ensuring the success of our collaborations.

To that end we have created a framework for collaborative research and scientific exchange in neurodegenerative disorders between academia, knowledge centers and Janssen's centers of excellence in Neuroscience. With a strong presence in Belgium as a medical innovator and a catalyst for building research partnerships in complex diseases, Janssen is encouraging the Benelux scientific community to attract top researchers to submit proposals for cutting-edge research that address major unmet medical needs in neurodegenerative disorders.

The initiative covers all aspects of translational research, including basic discovery, biomarker development and clinical research. Our aim is to encourage advanced research that will unravel the pathophysiological mechanisms of neurodegenerative disorders to generate therapeutic solutions, integrated care models and end-to-end approaches as possible disease strategies. The objective is to gain deeper insight into neurodegenerative diseases and ultimately accelerate delivery of breakthrough options to prevent, diagnose and treat them, ultimately help patients to live better lives.

Janssen will define the overall strategy for proposals but any original "out of the box" ideas that might shed new light on the understanding, diagnosis or treatment of neurodegenerative diseases will be evaluated.

Neurodegenerative diseases